Gateway 2011: 3M Drug Delivery Systems
Your online Gateway to 3M Drug Delivery Systems in 2011
3M Center, Bldg. 275-3E-10
St. Paul, MN 55144
1-800-643-8086
www.3M.com/DDS
Don't miss 3M Drug Delivery Systems at Respiratory Drug Delivery, May 3-6, 2011 in Berlin, Germany
About 3M Drug Delivery Systems
For more than 50 years, pharmaceutical companies worldwide have looked to 3M Drug Delivery
Systems for ingenious inhalation (dry powder inhaler and metered-dose inhaler) and transdermal (microneedle
and drug-in-adhesive) solutions to help their products meet the needs of the market. With proven international
success in technology, development, manufacturing and regulatory, partnering with 3M helps ensure critical
speed to market and the technical success of your project.
Join Us at RDD
We’ll be showcasing 3M’s Drug Powder Inhalers as well as a variety of other inhalation drug delivery devices
and components.
We’re also offering a DPI: Design for Manufacturing and Scale-Up (DFMSU) workshop as well as several
poster presentations highlighting the most performance data from our new Dry Powder Inhalers. See “New Dry
Powder Inhaler Data at RDD Europe” below to learn more.
Visit us at the conference or set up a meeting to find out how our depth of resources can help enable your next
project’s success.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
